150186-27-9

Basic information

• Product Name: Benzene, 1-(1,1-dimethylethyl)-4-(isocyanatomethyl)-
• CAS NO: 150186-27-9
• Molecular Formula: C12H15NO
• Molecular Weight: 189.257
• Mol File: 150186-27-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(1,1-dimethylethyl)-4-(isocyanatomethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(1,1-dimethylethyl)-4-(isocyanatomethyl)-(150186-27-9)
• EPA Substance Registry System: Benzene, 1-(1,1-dimethylethyl)-4-(isocyanatomethyl)-(150186-27-9)

Safety Data

• Hazardous Substances Data: 150186-27-9(Hazardous Substances Data)

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 39895-55-1 4-(1,1-dimethylethyl)-benzenemethanamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1002100-63-1 C₂₂H₂₇N₃O₂ 
• 1338065-29-4 1-[(4-tert-butylphenyl)methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea 
• 1338065-10-3 1-[(4-tert-butylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 
• 581811-41-8 N-(4-tert-butylbenzyl)-N'-(1,3-dimethyl-5-isoquinolinyl)urea 
• 852241-25-9 N-(4-tert-butylbenzyl)-N'-(1,3-dimethyl-5-isoquinolinyl)urea hydrochloride 

Relevant articles and documents

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.